Best Investment NewslettersStock & options newsletters

9 Best Biotech and Life-Science Stock Newsletters (2026)

Quick answer: The best biotech and life-science stock newsletters in our directory are Prosperity Investor (Stansberry Research), Back of the Napkin Bios, Double Blind Bets, Aaron's Idea Corner, BioCompounding's Newsletter, plus 4 more. Each one's price and cadence is checked against its official page (updated October 27, 2026).

Newsletters whose official pages say they focus on biotech, pharma or life-science companies. 9 listings, each checked against its official page. Not investment advice.

The list

PI
Paid

Prosperity Investor (Stansberry Research)

A monthly advisory on investing in health care and medical technology.

MonthlyPaid

HealthcareGrowth
BO
Paid

Back of the Napkin Bios

Long-only biotech and life-science stock ideas, each posted with a stated buy range.

Varies$250/mo or $1,000/yr

Stock picksHealthcare
DB
Paid

Double Blind Bets

Early-stage biotech explained for investors, beyond management pitches.

$39/mo or $399/yr

HealthcareStock picks
AI
Paid

Aaron's Idea Corner

A biotech investor sharing directional and volatility trade ideas.

$20/mo or $200/yr

HealthcareStock picks
BN
Paid

BioCompounding's Newsletter

One deep dive a month on a listed life-sciences company.

Monthly$30/mo or $299/yr

HealthcareStock picks
BB
Paid

Boutique Biotech

Boutique biotech and pharma investing insights since 2020.

$20/mo or $169/yr

HealthcareStock picks
JB
Paid

JNap's Biotech Thoughts

Thoughts on biotech and pharma stocks from Bio5C founder JNap.

$25/mo or $250/yr

Healthcare
BD
Paid

Biotech Distilled

Skeptical, filings-first research on public biotech and biopharma companies.

Deep dives plus daily updates$15/mo or $150/yr

HealthcareStock picks
BB
Paid

Biotech Blueprint

A weekly Friday briefing on biotech: trial readouts, FDA decisions and M&A.

Weekly$8/mo or $80/yr

Healthcare

Every listing on this page is plain HTML, so it works without JavaScript. JavaScript only adds the filters.

FAQ: best biotech and life-science stock newsletters

Why follow a biotech-only newsletter?

Biotech stocks often move on clinical trial results and regulatory decisions, which take specialist reading. These writers say they dig into trial data, papers and filings.

Are biotech stocks risky?

Yes. Many drugs tested in people never reach the market, so single-stock moves can be large. Nothing here is investment advice.

Is this list a ranking?

No. Our own newsletter is listed first where it qualifies; the rest are in a fixed editorial order. Featured spots are paid and labeled Sponsored.

Browse by

Strategy

Price

Cadence

Asset

Investor situation

Platform

Guides

Last updated: